Friday, June 17, 2022

10:00 Welcome & Introductions

Coronavirus Disease 2019 (COVID-19) Vaccines

10:15 Introduction

- Epidemiology of COVID-19 in young children
- Updates on vaccine effectiveness of COVID-19 vaccines in children and adolescents

11:45 Break

12:00 Moderna COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and efficacy in children ages 6 months through 5 years of age

12:45 Break

1:00 Safety, immunogenicity and efficacy of BNT162b2 in children ages 6 months through 4 years of age

mRNA COVID-19 vaccines in young children: Summary and Work Group interpretation

2:15 Public Comment

2:45 Adjourn

Saturday, June 18, 2022

10:00 Welcome & Introductions

Coronavirus Disease 2019 (COVID-19) Vaccines

10:15 Introduction

- Implementation of pediatric vaccines
- Evidence to recommendation Framework: mRNA COVID-19 vaccine in young children
- Clinical Considerations update
- Discussion

12:30 VOTE

- Moderna COVID-19 vaccine in children ages 6 months - 5 years
- Pfizer-BioNTech COVID-19 vaccine in children ages 6 months - 4 years

1:30 Adjourn

Acronyms

- CDC: Centers for Disease Control and Prevention
- CMS: Centers for Medicare and Medicaid Services
- COVID-19: Coronavirus disease 2019
- EtR: Evidence to Recommendations Framework
- FDA: Food and Drug Administration
- GRADE: Grading of Recommendations Assessment, Development and Evaluation
- HRSA: Health Resources and Services Administration
- IHS: Indian Health Service
- NCHHSTP: National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OIDP]
- NCIRD: National Center for Immunization & Respiratory Diseases [of CDC/OID]
- NCEZID: National Center for Emerging and Zoonotic Diseases [of CDC/OID]
- NIAID: National Institute of Allergy and Infectious Diseases
- OIDP: Office of Infectious Disease and HIV/AIDS Policy
- SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
- WG: Work Group
- WHO: World Health Organization
- VE: Vaccine Effectiveness